18690434

Source:http://linkedlifedata.com/resource/pubmed/id/18690434

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0011923, umls-concept:C0027651, umls-concept:C0027930, umls-concept:C0087111, umls-concept:C0182638, umls-concept:C0205360, umls-concept:C0599894, umls-concept:C1521840
pubmed:issue	1
pubmed:dateCreated	2008-12-5
pubmed:abstractText	Neurotensin (NT) and its high affinity receptor (NTR1) are involved in several neoplastic processes. Thus, NT-based radiopharmaceuticals are potential tracers for targeted diagnosis and therapy of NTR-positive tumours. A new analogue based on NT(8-13), NT-XIX, with the three enzymatic cleavage sites stabilised, was synthesised and tested.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101140988
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Neurotensin, http://linkedlifedata.com/resource/pubmed/chemical/Organotechnetium Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Radioisotopes, http://linkedlifedata.com/resource/pubmed/chemical/Radiopharmaceuticals, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Neurotensin, http://linkedlifedata.com/resource/pubmed/chemical/Rhenium
pubmed:status	MEDLINE
pubmed:month	Jan
pubmed:issn	1619-7089
pubmed:author	pubmed-author:BläuensteinPeterP, pubmed-author:BlancAlainA, pubmed-author:García-GarayoaElisaE, pubmed-author:MaesVeroniqueV, pubmed-author:SchubigerP AugustPA, pubmed-author:TourwéDirkD
pubmed:issnType	Electronic
pubmed:volume	36
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	37-47
pubmed:meshHeading	pubmed-meshheading:18690434-Amino Acid Sequence, pubmed-meshheading:18690434-Animals, pubmed-meshheading:18690434-Biological Transport, pubmed-meshheading:18690434-Cell Line, Tumor, pubmed-meshheading:18690434-Half-Life, pubmed-meshheading:18690434-Humans, pubmed-meshheading:18690434-Mice, pubmed-meshheading:18690434-Molecular Weight, pubmed-meshheading:18690434-Neoplasms, pubmed-meshheading:18690434-Neurotensin, pubmed-meshheading:18690434-Organotechnetium Compounds, pubmed-meshheading:18690434-Radioisotopes, pubmed-meshheading:18690434-Radiopharmaceuticals, pubmed-meshheading:18690434-Receptors, Neurotensin, pubmed-meshheading:18690434-Rhenium, pubmed-meshheading:18690434-Staining and Labeling, pubmed-meshheading:18690434-Tissue Distribution, pubmed-meshheading:18690434-Tomography, Emission-Computed, Single-Photon, pubmed-meshheading:18690434-Tomography, X-Ray Computed
pubmed:year	2009
pubmed:articleTitle	A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours.
pubmed:affiliation	Paul Scherrer Institute, Center for Radiopharmaceutical Science, CH-5232, Villigen PSI, Switzerland. elisa.garcia@psi.ch
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't